<DOC>
	<DOCNO>NCT01440595</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , antiviral activity grazoprevir ( MK-5172 ) administer concomitantly peg-interferon alfa-2b ( Peg-IFN ) ribavirin ( RBV ) treatment-naïve participant chronic genotype 2 ( GT2 ) genotype 3 ( GT3 ) hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>Grazoprevir ( MK-5172 ) With Peg-Interferon Ribavirin Participants With Chronic Genotype 2 3 Hepatitis C ( MK-5172-012 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Body weight ≥ 88 lbs ≤ 275 lb Documented chronic Hepatitis C ( CHC ) GT2 GT3 infection No know cirrhosis Agrees use two acceptable method birth control study 6 month last dose study drug Chest Xray within last 6 month Eye exam within last 6 month Known human immunodeficiency virus ( HIV ) positive coinfected active hepatitis B virus ( positive Hepatitis B surface antigen ) Prior approve investigational treatment hepatitis C Evidence hepatocellular carcinoma Diabetic and/or high blood pressure clinically significant eye exam finding Preexisting psychiatric condition Clinical diagnosis abuse certain substance within specify timeframes Known medical condition could interfere participation Active suspect cancer within last 5 year Female pregnant , breastfeeding , expect conceive donate egg Male plan impregnate partner donate sperm Male pregnant female partner Chronic hepatitis cause HCV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>